Sionna Therapeutics (NASDAQ:SION) Director Sells $2,341,097.96 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 52,397 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $44.68, for a total transaction of $2,341,097.96. Following the completion of the sale, the director directly owned 2,967,722 shares in the company, valued at $132,597,818.96. This represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14.
• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54.
• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.57, for a total transaction of $84,237.30.

Sionna Therapeutics Price Performance

Shares of SION opened at $38.35 on Friday. The firm’s 50 day simple moving average is $38.08 and its 200 day simple moving average is $38.66. The company has a market capitalization of $1.73 billion, a P/E ratio of -19.67 and a beta of 3.01. Sionna Therapeutics, Inc. has a 1-year low of $10.97 and a 1-year high of $46.46.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15. On average, equities analysts anticipate that Sionna Therapeutics, Inc. will post -2.44 earnings per share for the current year.

Institutional Investors Weigh In On Sionna Therapeutics

Several institutional investors have recently bought and sold shares of SION. Goldman Sachs Group Inc. purchased a new stake in Sionna Therapeutics during the 1st quarter valued at about $667,000. Woodline Partners LP purchased a new position in Sionna Therapeutics during the 1st quarter valued at about $837,000. Geode Capital Management LLC increased its holdings in Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after purchasing an additional 153,712 shares during the period. Rhumbline Advisers purchased a new position in Sionna Therapeutics during the 2nd quarter valued at about $307,000. Finally, New York State Common Retirement Fund purchased a new stake in Sionna Therapeutics in the 2nd quarter worth approximately $118,000.

Analysts Set New Price Targets

A number of research firms recently weighed in on SION. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Citigroup began coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating for the company. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Finally, BTIG Research restated a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $50.57.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.